Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554516341> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2554516341 endingPage "1580" @default.
- W2554516341 startingPage "1575" @default.
- W2554516341 abstract "Purpose: To evaluate the efficacy of topical apraclonidine in reducing pain and subconjunctival hemorrhage (SCH) after intravitreal injections (IViT). Methods: A prospective, randomized, double-blinded study. Thirty-nine patients were examined twice, at each monthly IViT of 1.25 mg/0.05 mL bevacizumab. Patients were randomly assigned to receive either topical apraclonidine 0.5% or placebo to the treated eye, 30 minutes before the first IViT. At their second IViT, the intervention was switched. Thirty minutes after the injection, SCH size was measured by a slit lamp, and pain was assessed by the numerical rating scale (NRS-11). Results: Mean pain score was 1.69 (SD ±1.44) in the apraclonidine group and 3.28 (SD ±2.27) in the control group ( P < 0.001). Phakic patients had a greater pain reduction after topical apraclonidine ( P < 0.001). Subconjunctival hemorrhage incidence was 41% in the apraclonidine group and 51.3% in the control group ( P = 0.503). Mean SCH size was 1.71 mm 2 (SD ±5.83) in the apraclonidine group and 3.25 mm 2 (SD ±6.41) in the control group ( P = 0.253). After topical apraclonidine, there was a smaller reduction in SCH size in patients with choroidal neovascularization or hypertension ( P = 0.003 and 0.044, respectively), and a greater reduction in phakic patients ( P = 0.048). Conclusion: Topical apraclonidine 0.5%, administered 30 minutes before IViT, significantly decreased pain by a factor of 1.94. It did not decrease the incidence or size of SCH in the entire cohort, but only in several subpopulations." @default.
- W2554516341 created "2016-11-30" @default.
- W2554516341 creator A5004052018 @default.
- W2554516341 creator A5034418754 @default.
- W2554516341 creator A5040122352 @default.
- W2554516341 creator A5055095563 @default.
- W2554516341 creator A5065918119 @default.
- W2554516341 creator A5077443224 @default.
- W2554516341 creator A5079301470 @default.
- W2554516341 date "2017-08-01" @default.
- W2554516341 modified "2023-09-27" @default.
- W2554516341 title "TOPICAL APRACLONIDINE REDUCES PAIN AFTER INTRAVITREAL INJECTIONS" @default.
- W2554516341 cites W1511853499 @default.
- W2554516341 cites W1599233700 @default.
- W2554516341 cites W1927855521 @default.
- W2554516341 cites W1981159156 @default.
- W2554516341 cites W1982304923 @default.
- W2554516341 cites W1984982865 @default.
- W2554516341 cites W1999611557 @default.
- W2554516341 cites W2012952191 @default.
- W2554516341 cites W2020761135 @default.
- W2554516341 cites W2029119558 @default.
- W2554516341 cites W2039446733 @default.
- W2554516341 cites W2052600703 @default.
- W2554516341 cites W2079546021 @default.
- W2554516341 cites W2090780299 @default.
- W2554516341 cites W2127987040 @default.
- W2554516341 cites W2132625410 @default.
- W2554516341 cites W2157912229 @default.
- W2554516341 cites W95427770 @default.
- W2554516341 doi "https://doi.org/10.1097/iae.0000000000001397" @default.
- W2554516341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27841849" @default.
- W2554516341 hasPublicationYear "2017" @default.
- W2554516341 type Work @default.
- W2554516341 sameAs 2554516341 @default.
- W2554516341 citedByCount "7" @default.
- W2554516341 countsByYear W25545163412018 @default.
- W2554516341 countsByYear W25545163412019 @default.
- W2554516341 countsByYear W25545163412020 @default.
- W2554516341 countsByYear W25545163412021 @default.
- W2554516341 countsByYear W25545163412023 @default.
- W2554516341 crossrefType "journal-article" @default.
- W2554516341 hasAuthorship W2554516341A5004052018 @default.
- W2554516341 hasAuthorship W2554516341A5034418754 @default.
- W2554516341 hasAuthorship W2554516341A5040122352 @default.
- W2554516341 hasAuthorship W2554516341A5055095563 @default.
- W2554516341 hasAuthorship W2554516341A5065918119 @default.
- W2554516341 hasAuthorship W2554516341A5077443224 @default.
- W2554516341 hasAuthorship W2554516341A5079301470 @default.
- W2554516341 hasConcept C141071460 @default.
- W2554516341 hasConcept C142724271 @default.
- W2554516341 hasConcept C168563851 @default.
- W2554516341 hasConcept C204787440 @default.
- W2554516341 hasConcept C27081682 @default.
- W2554516341 hasConcept C42219234 @default.
- W2554516341 hasConcept C71924100 @default.
- W2554516341 hasConceptScore W2554516341C141071460 @default.
- W2554516341 hasConceptScore W2554516341C142724271 @default.
- W2554516341 hasConceptScore W2554516341C168563851 @default.
- W2554516341 hasConceptScore W2554516341C204787440 @default.
- W2554516341 hasConceptScore W2554516341C27081682 @default.
- W2554516341 hasConceptScore W2554516341C42219234 @default.
- W2554516341 hasConceptScore W2554516341C71924100 @default.
- W2554516341 hasIssue "8" @default.
- W2554516341 hasLocation W25545163411 @default.
- W2554516341 hasLocation W25545163412 @default.
- W2554516341 hasOpenAccess W2554516341 @default.
- W2554516341 hasPrimaryLocation W25545163411 @default.
- W2554516341 hasRelatedWork W1983403674 @default.
- W2554516341 hasRelatedWork W1984226278 @default.
- W2554516341 hasRelatedWork W2022301355 @default.
- W2554516341 hasRelatedWork W2183694216 @default.
- W2554516341 hasRelatedWork W3159250744 @default.
- W2554516341 hasRelatedWork W4233016836 @default.
- W2554516341 hasRelatedWork W4256514411 @default.
- W2554516341 hasRelatedWork W4292236216 @default.
- W2554516341 hasRelatedWork W4312225894 @default.
- W2554516341 hasRelatedWork W2083697902 @default.
- W2554516341 hasVolume "37" @default.
- W2554516341 isParatext "false" @default.
- W2554516341 isRetracted "false" @default.
- W2554516341 magId "2554516341" @default.
- W2554516341 workType "article" @default.